NCT02267967View on ClinicalTrials.gov

Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

August 23, 2017

Study Completion Date

August 23, 2017

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Sulfatinib

Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.

Trial Locations (7)

100032

Peking Union Medical College Hospital, Beijing

100071

the 307 Hospital of People's Liberation Army, Beijing

100142

Beijing Cancer Hospital, Beijing

200433

Shanghai Pulmonary Hospital, Shanghai

310006

The first affiliated hospital, Zhejiang University, Hangzhou

510060

Sun Yat-sen University Cancer Center, Guangzhou

610047

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

Hutchison Medipharma Limited

INDUSTRY

NCT02267967 - Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter